EXPRESSION CORE

表达核心

• 批准号: 8143200
• 负责人: PATRICIA K DONAHOE
• 金额: $ 7.96万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8143200
• 关键词: Candidate Disease Gene; Comorbidity; Development; Diaphragmatic Hernia; Dominant-Negative Mutation; Drosophila genus; Gene Mutation; Genes; Heart; Human; Immunohistochemistry; In Situ; Individual; Learning; Liver; Lung; Organ; Organ Culture Techniques; Pattern; Proteins; Protocols documentation; RNA; RNA Interference; Respiratory Diaphragm; System; Techniques; Technology; Time; Tissues; Work; design; interest; programs; protein expression

The Expression Core will determine the developmental times and tissues in which candidate genes identified by Projects I, II and III are expressed. These studies will determine both RNA and/or protein expression patterns using immunohistochemistry or in situ hybridiation, whichever is deemed appropriate. Further, genes of particular interest will undergo analysis using the RCAS-TVA system for tissue expression of both wildtype and dominant negative proteins. Diaphragm whole mounts are difficult to examine, but the director and staff of this core have learned the necessary techniques from Dr. Akerman. Lung organ culture has been in use in the lab for 20 years. RNAi technology has been used by the Pis for the past 8 years. Together with the Drosophila Core, RNAi technology will be uniquely available for the program project. Brief descriptions of the protocols that Dr. Loscertales uses routinely which will be instrumental in analyzing CDH candidate genes follow.

表达核心将确定表达项目I，II和III鉴定的候选基因的发育时间和组织。这些研究将使用免疫组织化学或原位杂交来确定RNA和/或蛋白质表达模式，以适当的为准。 此外，具有特别感兴趣的基因将使用RCAS-TVA系统进行分析，以用于野生型和显性负蛋白的组织表达。隔膜整个坐骑很难检查，但是该核心的董事和工作人员已经从Akerman博士那里学到了必要的技术。肺部的培养在实验室已有20年。在过去的8年中，PI已使用RNAi技术。 RNAi技术将与果蝇核心一起用于该计划项目。简要描述了Loscertales博士常规使用的方案，这些方案将在分析CDH候选基因的过程中发挥作用。